Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can
transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D)
who secrete proinsulin and little/no C-peptide.